AI alliances will push pharma refocus on patent bundles and licensing
Pharma companies say AI’s potential to make R&D models more efficient and less expensive will drive the development of therapeutics that require different IP strategies
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
